Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression
| Autor: | Min Ho Park, Jin Seong Cho, Yong-Min Na |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male endocrine system Cancer Research medicine.medical_specialty Time Factors endocrine system diseases Levothyroxine Thyrotropin Thyroid Lobectomy Risk Assessment Gastroenterology Drug Administration Schedule Papillary thyroid cancer Benign tumor Thyroid carcinoma Hypothyroidism Thyroid-stimulating hormone Risk Factors Internal medicine medicine Humans Euthyroid Thyroid Neoplasms Risk factor Retrospective Studies business.industry General Medicine medicine.disease Thyroxine Treatment Outcome Oncology Thyroid Cancer Papillary Thyroidectomy Female business Biomarkers medicine.drug |
| Zdroj: | Anticancer Research. 41:5713-5721 |
| ISSN: | 1791-7530 0250-7005 |
| Popis: | BACKGROUND/AIM Thyroid lobectomy may cause post-lobectomy hypothyroidism. We investigated the difference in levothyroxine (LT4) supplementation and cessation between patients with benign disease and those with papillary thyroid carcinoma (PTC) and found that the rate of LT4 cessation could be decreased after thyroid-stimulating hormone (TSH) suppression in PTC. PATIENTS AND METHODS We retrospectively reviewed 88 patients with benign tumor and 463 patients with PTC and investigated the risk factors for LT4 supplementation after thyroid lobectomy. RESULTS During the median follow-up of 73.0 months, 207 (37.6%) patients maintained the euthyroid state, while 344 (62.4%) patients continued LT4 supplementation for LT4 replacement or TSH suppression. In patients with benign tumors, only high pre-TSH level (>1.98 mIU/l) was a significant risk factor (odds ratio [OR]=10.09). However, in patients with PTC, pre-TSH level ≥1.98 mIU/l (OR=3.28), pregnancy planning (OR=2.97), and age ≥42.5 years (OR=1.94) were significant risk factors. Moreover, the most potent risk factor was tumor aggressiveness (OR=4.00), which was found to be more significant than high pre-TSH. The overall rate of LT4 cessation in all patients was 37.6%; however, in the 303 patients who underwent the LT4-Off trial, there was no difference in the rate in the benign tumor, low-risk PTC, and intermediate-risk PTC groups (66.2%, 68.8%, and 70.8%, respectively; p=0.886). CONCLUSION When post-lobectomy TSH levels were adequate and the risk of recurrence was reduced, LT4 cessation in PTC could be achieved at the same rate as that in benign tumors, regardless of the duration of TSH suppression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|